Table 1 Baseline characteristics, profile of autoantibodies, and clinical manifestations of 350 SLE-TP patients

Female gender, n(%)

313(89.4)

194 (86.6)

145 (92.9)

0.055

Age (years)

33 (27,43)

33 (27,44)

33(26,42)

0.939

Disease duration (years)

10.0(6.7,14.3)

9.6 (5.6,13.9)

10.8 (7.2,14.7)

0.321

SLEDAI-2k

3(1,7)

3(1,8)

2(1,7)

0.282

Baseline platelet count (×10⁹/L)

68.5(40,90)

61(33,86)

76.5(54, 90)

<0.001

Severe (<20 × 10⁹/L), n(%)

48(13.7)

35(18.0)

13(8.3)

Moderate (20–50 × 10⁹/L), n(%)

69(19.7)

47(24.2)

22(14.1)

<0.001

Mild (50–100 × 10⁹/L), n(%)

233(66.6)

112(57.7)

121(77.6)

Skin and mucous membranes, n(%)

149(42.6)

77(39.7)

72(46.2)

0.224

Arthritis, n(%)

124(35.4)

58(29.9)

66(42.3)

0.016

Serositis, n(%)

68(19.4)

29(14.9)

39(25.0)

0.018

Neurological involvement, n(%)

63(18.0)

38(19.6)

25(16.0)

0.389

Nephropathy, n(%)

140(40.0)

72(37.1)

68(43.6)

0.219

HGB (×10¹²/L)

119.5(102,135)

119(102,137)

120.5(104,133)

0.795

Anti-double stranded DNA (anti-dsDNA) antibody, n(%)

92(26.3)

42(21.8)

50(32.1)

0.028

Anti-Sm antibody, n(%)

85(24.3)

39(20.1)

46(29.5)

0.042

Anti-RNP antibody, n(%)

145(41.4)

64(33.0)

81(51.9)

<0.001

Anti-SSA antibody, n(%)

204(58.3)

105(54.1)

99(63.5)

0.078

Anti-SSB antibody, n(%)

50(14.3)

23(11.9)

27(17.3)

0.147

Anti-ribosomal P protein (anti-RibP) antibody, n(%)

78(22.3)

45(23.2)

33(21.2)

0.648

Anti-nucleosome antibody (ANuA), n(%)

48(13.7)

33(17.0)

15(9.6)

0.046

Anti-histone antibody (AHA), n(%)

58(16.6)

37(19.1)

21(13.5)

0.161

APS, n(%)

49(14.0)

49(29.3)

0

<0.001

Thrombosis, n(%)

44(12.6)

37(19.1)

7(4.5)

<0.001

Glucocorticoids, n(%)

350 (100)

194 (100)

156 (100)

1

Immunosuppressant, n(%)

305 (87.1)

169 (87.1)

136 (87.2)

0.985

Anticoagulant therapy, n(%)

59 (16.9)

46 (23.7)

13 (8.3)

<0.001

Antiplatelet therapy, n(%)

128 (36.6)

79 (40.7)

49 (31.4)

0.072